CN1324613A - 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 - Google Patents

用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 Download PDF

Info

Publication number
CN1324613A
CN1324613A CN01119258A CN01119258A CN1324613A CN 1324613 A CN1324613 A CN 1324613A CN 01119258 A CN01119258 A CN 01119258A CN 01119258 A CN01119258 A CN 01119258A CN 1324613 A CN1324613 A CN 1324613A
Authority
CN
China
Prior art keywords
paclitaxel
tumor
medicine
albumin
microgranule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN01119258A
Other languages
English (en)
Other versions
CN1198609C (zh
Inventor
M·法茨安尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
ACS Dobfar SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1324613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ACS Dobfar SpA filed Critical ACS Dobfar SpA
Publication of CN1324613A publication Critical patent/CN1324613A/zh
Application granted granted Critical
Publication of CN1198609C publication Critical patent/CN1198609C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

用白蛋白稳定的紫杉醇的微粒在制备用于治疗对紫杉醇敏感的实体瘤的药物方面的应用,以及由此获得的药物。

Description

用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的 药物方面的应用和由此获得的药物
本发明涉及治疗对紫杉醇(Paclitaxel)敏感的肿瘤的药物，以及掺和了紫杉醇的白蛋白微粒(通称为ABI 007)在制备该药物中的应用。
紫杉醇是一种文献中熟知的物质，它对大量肿瘤(例如卵巢瘤，肺瘤，头和颈瘤，膀胱瘤和乳腺瘤)具有重要的临床活性。
紫杉醇不溶于水。为了使它成为可溶性和适合静脉内注射，将它与表面活性剂(例如聚乙氧基化蓖麻油，注册名称为“Cremophor EL”)混合，以及与约50％无水酒精USP(作为紫杉醇的载体)混合：该混合物由Bristol-Myers Squibb取得了专利，注册名称为“紫杉醇”(“Taxol”)，下文将提及它，为简便起见。表面活性剂和无水酒精的存在除了其它副作用之外还具有严重的缺点，例如，强过敏性。
在任何情况下，以很长时间施用(而且只能通过静脉内注射施用)紫杉醇，试图将该产品的毒性作用减到最小。
为了克服上述缺点，所述Bristol-Myers Squibb获得了组合物的专利(欧洲专利申请EP-A-0584001、EP-A-0783885、EP-A-0783886和美国专利US 5641803和US 5670537)，所述组合物除了含紫杉醇之外还包含能阻止严重的过敏反应的其它物质或药物。
根据已知技术，如前述专利描述的那样，对接受治疗的患者静脉内施用135～175mg/m2患者体表面的紫杉醇，每次施药都是很缓慢地、在约3小时的时间中进行的：最重要的是总是应用上述药物。
US 5439686、US 5498421和US 5560933描述了掺和了紫杉醇的白蛋白微粒：国际上以符号ABI 007标记这些粒子。下文提到这些微粒时为简便起见应用这个名称。
ABI 007实际上是一种通过人白蛋白USP稳定化的紫杉醇的制剂，它能分散在可直接注射的生理溶液中，不含毒性乳化剂。
意外地发现了，ABI 007可被用于制备药物，其中，ABI 007作为生理溶液中的分散体以2～8mg/ml这些溶液的浓度存在，而且可将该药物直接注入对与紫杉醇敏感性肿瘤相关的区供血的那些动脉，施药时间比已知技术中可能的短得多，而且只重复数次。
与上述以前已知的专利的教导相比，可以注意到，按本发明，应用ABI 007获得这样的药物：它们的应用能使患者比用已知的静脉内施药方法施用剂量高得多的紫杉醇而且输注时间短得多，获得良好的结果(响应百分数极高且令人意外)，在所有情况下观察到很低的毒性。
更具体地说，动脉内施用本发明的药物可以间隔3～4周，获得治疗上很好的结果，即，高于71％的治疗响应百分数(与用紫杉醇常规治疗达到的40％相比，例如在头和颈癌的治疗中)。
更具体地说，可应用本发明的药物治疗患有对紫杉醇敏感的肿瘤的患者获得意外的结果，将该药物直接注射入对肿瘤相关的区供血的动脉，注意使用包含190～500mg ABI 007的一定量的药物，并且在约25～60分钟内完成注射。然后重复2～5次类似的动脉内注射，彼此间隔3～5周。
已证实对所述治疗有响应的肿瘤是鳞状细胞癌，包括肺、头和颈、子宫和肛门道的某些肿瘤。
从进行的试验可见，优选地，用于动脉内治疗肿瘤的药物量包含200～300mg ABI 007/m2患者体表面(每次施药)，而且分散体的每次单一剂量的施药大约进行30分钟。
描述了一些涉及不同类别和位置的肿瘤治疗的实施例，是为了阐释对本发明的理解和本发明的特征。
实施例1
用ABI 007在生理溶液中的分散体(呈白蛋白的微粒形式的紫杉醇)分别以220、230、250和275mg/m2体表面的剂量分独立的四次接连动脉内注射(彼此间隔4周)入髂内动脉来治疗一名57岁的女患者(PR)，该患者患有肛门道癌的骨盆复发，以前接受过化学疗法、放射疗法和手术治疗，经判断不宜手术。
注射的分散体浓度为6mg ABI 007/ml它们的溶液。
计算机体层摄影术跟踪肿瘤的减小。观察到显著的肿瘤减小并且认为肿瘤块实际上完全消退了，进行了外科手术，表明不存在组织瘤。
实施例2
对一名64岁的女患者(ZN)施用ABI 007：接连4个周期分别以210、230、200和200 mg/m2的剂量，以4mg/ml的浓度施药入左舌动脉，所述患者的左半边舌患有很大的瘤形成，以前从未接受过任何治疗。
通过临床检查和磁共振跟踪对治疗的响应，因为存在固定的假牙。
观察到显著的肿瘤消退，治疗结束后一个月估计消退90％，提议做了外科手术，表明组织不存在肿瘤。
实施例3
对一名61岁的男患者(BP)施用ABI 007:3个周期(间隔4周)以240mg/m2的剂量和3mg/ml的浓度施药入外部的颈动脉，所述患者患有在右颈侧淋巴结处转移的右喉咽癌，以前从未接受过任何治疗。通过计算机体层摄影术和临床检查观察到了治疗响应，在喉咽部以前的肿瘤部位进行了多次深度活组织检查，表明组织不存在瘤形成。
淋巴结转移瘤尺寸也减少了80％以上，并且通过外科手术除去了在该水平存在的肿瘤。
实施例4
对一名37岁的女患者(EP)施用ABI 007:4个周期(间隔4周)，每个周期以250mg/m2的剂量、7mg/ml的浓度施药入髂内动脉，所述患者患有肛门道的复发癌，以前接受过放射化学疗法。
通过妇科检查和计算机体层摄影术观察到了治疗响应，提议做了新的外科手术，表明组织不存在肿瘤。实施例5
对一名59岁的男患者(GC)施用ABI 007：分别以200、240和260mg/m2的剂量、7.5mg/ml的浓度施药入髂内动脉，所述患者患有肛门道的复发癌，以前接受过放射化学疗法。
通过临床检查和经直肠的echoendosonography观察到了响应，提议做了外科手术，表明组织不存在肿瘤。

Claims (4)

1．用白蛋白稳定的紫杉醇的微粒在制备用于治疗对紫杉醇敏感的实体瘤、特别是鳞状细胞癌的药物方面的应用，所述药物包含所述微粒在生理溶液中的分散体，其中，所述微粒以2～8mg/ml该溶液的浓度存在。
2．权利要求1的微粒的应用，其特征在于，所述微粒在它们的分散体中的浓度为3～7.5mg/ml生理溶液。
3．一种用于治疗对紫杉醇敏感的实体瘤的药物，其特征在于，它包含用白蛋白稳定的紫杉醇的微粒在生理溶液中的分散体，其中，所述微粒的浓度为2～8mg/ml所述溶液。
4．权利要求3的药物，其特征在于，所述微粒在所述分散体中的浓度为3～7.5mg/ml生理溶液。
CNB011192585A 2000-05-18 2001-05-18 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 Ceased CN1198609C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI2000A001107 2000-05-18

Publications (2)

Publication Number Publication Date
CN1324613A true CN1324613A (zh) 2001-12-05
CN1198609C CN1198609C (zh) 2005-04-27

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011192585A Ceased CN1198609C (zh) 2000-05-18 2001-05-18 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物

Country Status (23)

Country Link
US (1) US6652884B2 (zh)
EP (1) EP1155692B1 (zh)
JP (1) JP2001354559A (zh)
KR (2) KR20010105248A (zh)
CN (1) CN1198609C (zh)
AT (1) ATE267594T1 (zh)
AU (1) AU781517B2 (zh)
BR (1) BR0102040A (zh)
CA (1) CA2345482A1 (zh)
DE (1) DE60103453T2 (zh)
DK (1) DK1155692T3 (zh)
ES (1) ES2221874T3 (zh)
HK (1) HK1040368A1 (zh)
HU (1) HU229909B1 (zh)
IL (1) IL142674A0 (zh)
IT (1) ITMI20001107A1 (zh)
MX (1) MXPA01004980A (zh)
NO (1) NO330511B1 (zh)
NZ (1) NZ511201A (zh)
PT (1) PT1155692E (zh)
RU (1) RU2270003C2 (zh)
TR (1) TR200101353A2 (zh)
ZA (1) ZA200103755B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US9671406B2 (en) 2006-03-31 2017-06-06 Abraxis Bioscience, Llc SPARC and methods of use thereof

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA3054535A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
EA015781B1 (ru) * 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
RU2483714C2 (ru) 2007-03-07 2013-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
US8927019B2 (en) 2007-06-01 2015-01-06 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
RS59896B1 (sr) 2009-04-15 2020-03-31 Abraxis Bioscience Llc Kompozicije nanočestica bez priona i postupci povezani sa njima
CA2793536C (en) 2010-03-26 2019-10-01 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
HUE030207T2 (en) 2010-03-29 2017-04-28 Abraxis Bioscience Llc Cancer Treatment Procedures
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
AU2011261685B2 (en) 2010-06-04 2016-02-11 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer
SG10201606406PA (en) 2011-04-28 2016-09-29 Abraxis Bioscience Llc Intravascular delivery of nanoparticle compositions and uses thereof
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN110279864A (zh) 2013-03-12 2019-09-27 阿布拉科斯生物科学有限公司 治疗肺癌的方法
KR20150126671A (ko) * 2013-03-13 2015-11-12 아브락시스 바이오사이언스, 엘엘씨 소아 고형 종양의 치료 방법
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
EP3313401B1 (en) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
TWI660728B (zh) 2018-02-09 2019-06-01 國立交通大學 胺基喹唑啉衍生物及其醫藥組合物與用途
MX2020009740A (es) 2018-03-20 2021-01-20 Abraxis Bioscience Llc Metodos para el tratamiento de trastornos del sistema nervioso central mediante la administracion de nanoparticulas de un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y una albumina.
MX2022004989A (es) 2019-10-28 2022-07-21 Abraxis Bioscience Llc Composiciones farmaceuticas de albumina y rapamicina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
JP3746293B2 (ja) 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CN100462066C (zh) * 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
WO2000006152A1 (en) 1998-07-30 2000-02-10 Novopharm Biotech, Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US9671406B2 (en) 2006-03-31 2017-06-06 Abraxis Bioscience, Llc SPARC and methods of use thereof

Also Published As

Publication number Publication date
EP1155692B1 (en) 2004-05-26
AU781517B2 (en) 2005-05-26
ITMI20001107A1 (it) 2001-11-18
RU2270003C2 (ru) 2006-02-20
JP2001354559A (ja) 2001-12-25
DE60103453T2 (de) 2005-06-23
TR200101353A3 (tr) 2001-12-21
PT1155692E (pt) 2004-09-30
ES2221874T3 (es) 2005-01-16
EP1155692A1 (en) 2001-11-21
CA2345482A1 (en) 2001-11-18
ZA200103755B (en) 2001-11-15
NZ511201A (en) 2002-11-26
CN1198609C (zh) 2005-04-27
TR200101353A2 (tr) 2001-12-21
NO20012409D0 (no) 2001-05-16
HK1040368A1 (en) 2002-06-07
NO330511B1 (no) 2011-05-09
DE60103453D1 (de) 2004-07-01
US20010046961A1 (en) 2001-11-29
AU3876501A (en) 2001-11-22
US6652884B2 (en) 2003-11-25
NO20012409L (no) 2001-11-19
HUP0102039A2 (hu) 2002-05-29
HU229909B1 (en) 2014-12-29
MXPA01004980A (es) 2002-08-06
HU0102039D0 (en) 2001-07-30
DK1155692T3 (da) 2004-08-09
KR20080091747A (ko) 2008-10-14
KR20010105248A (ko) 2001-11-28
BR0102040A (pt) 2002-03-19
ATE267594T1 (de) 2004-06-15
ITMI20001107A0 (it) 2000-05-18
IL142674A0 (en) 2002-03-10
HUP0102039A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
CN1198609C (zh) 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物
Sartor Eligard: leuprolide acetate in a novel sustained-release delivery system
CN1234416C (zh) 持续释放疏水药物的组合物及其制备方法
US20140294964A1 (en) Compositions and methods for treating cancer with dacarbazine nanoemulsions
JP4489356B2 (ja) 浸透促進剤
JPS58116421A (ja) インシユリン放出剤
CN107837229A (zh) 一种缓释阿霉素脂质体的温敏水凝胶制剂及制备方法
ZA200208167B (en) Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents.
Yu et al. Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice
CN110870918A (zh) 包含氨基酸类营养素和抗肿瘤化疗药物的药物组合物及其应用
JPH07116031B2 (ja) 制癌剤
CN108309943A (zh) 一种基于药物颗粒的复方制剂
JPH07165582A (ja) 免疫抗癌剤の抗癌効果増強剤
CN1838942A (zh) 递送疏水性药物的组合物和方法
JP3442866B2 (ja) 難水溶性薬物含有徐放性製剤
JPH10147534A (ja) 腫瘍新生血管阻害物質及び医薬組成物
CN109498547A (zh) 一种平阳霉素局部注射制剂及其制备方法
WO2001076559A1 (en) Method 0f administration of paclitaxel-plasma protein formulation
RU2676279C1 (ru) Стабильное противоопухолевое лекарственное средство, способ его получения и применения
CN117357534A (zh) 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途
EP1354589A1 (en) Angiogenesis inhibitors
CN113230420A (zh) 包含亚甲蓝类活体染料的水基乳剂、该乳剂的应用以及包含该乳剂的药物组合物
CN113230212A (zh) 包含氨基酸类化合物的水基乳剂、该乳剂的应用以及包含该乳剂的药物组合物
CN103889222A (zh) 含有紫杉醇乳清酸酯的药物组合物
JPH11171787A (ja) ドラスタチン１０誘導体を含有するマイクロスフエア製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABRAXIS BIOSCIENCE INC

Free format text: FORMER OWNER: ACS DOBFAR SPA

Effective date: 20070713

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20070713

Address after: American California

Patentee after: American Bioscience, Inc.

Address before: Italy triy Arnold

Patentee before: Acs Dobfar SPA

ASS Succession or assignment of patent right

Owner name: ABRAXIS BIOSCIENCE CO., LTD.

Free format text: FORMER OWNER: ABRAXIS BIOSCIENCE

Effective date: 20090821

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090821

Address after: American California

Patentee after: Abraxis Bioscience, LLC

Address before: American California

Patentee before: American Bioscience, Inc.

IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20171109

Decision number of declaring invalidation: 33779

Granted publication date: 20050427

IW01 Full invalidation of patent right